Clinical trials: Oxycodone
Conscious Sedation During Endoscopic Retrograde Choledochopancreatography
Efficacy of Oxycodone-propofol Combination Compared With a Fentanyl-propofol Combination on Conscious Sedation Effect and Early Cognitive Function During Therapeutic Endoscopic Retrograde Cholangio-pancreatography
To evaluate and compare the sedative effect and effects on early period cognitive function of a fentanyl-propofol Combination (FP) regimen with a oxycodone-propofol(OP) combination during the endoscopic retrograde…
- Trial name
- NCT03755609
- Testing
- Oxycodone, fentanyl
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Cancer Pain
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.
- Trial name
- SWITCH (NCT02660229)
- Testing
- Oxycodone Hydrochloride, Morphine Sulphate
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Mundipharma Korea Ltd
Post Operative Pain
Comparison of Tramacet Versus Percocet in Post Surgical Patients
Opioid naive patients are randomized to receive either TRAMACET or PERCOCET at the time of discharge following mild to moderate pain risk surgery. The following will be assessed: 1) Brief pain inventory (BPI) for the month.
- Trial name
- NCT02361567
- Testing
- Tramacet, Percocet
- Where
- Canada
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Postoperative Pain, Opioid Induced Constipation
A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
Objectives: Primary objective: To demonstrate that the treatment with OXN PR tablets up to 72 hrs after surgery is superior to the treatment with OxyPR with regards to constipation in subjects with postoperative pain after…
- Trial name
- NCT01109511
- Testing
- naloxone, oxycodone
- Where
- Norway
- Volunteers
- 85 people
- Sponsor
- Ullevaal University Hospital
Pain, Postoperative
Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
This study will evaluate the safety and tolerability based on the incidence of adverse experiences of buprenorphine sublingual spray (0.5 milligrams [mg] three times daily [TID]) compared with standard post-operative narcotic…
- Trial name
- NCT03254459
- Testing
- Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- INSYS Therapeutics Inc
Severe Caner Pain
A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion
Assessing the safety and tolerability of Oxycodone Hydrochloride 50mg/mL in subjects with severe cancer pain.
- Trial name
- NCT00626600
- Testing
- Oxycodone Hydrochloride
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Mundipharma Research Limited
Pain
Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
- Trial name
- NCT00412100
- Testing
- Oxycodone naloxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain
Oxycodone-naloxone in Relieving Opioid-related Constipation
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects…
- Trial name
- NCT00412152
- Testing
- Oxycodone nalaxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Cancer, Pain
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient's specific type of "chronic cancer pain".
- Conditions
- Cancer, Pain, Constipation
- Trial name
- NCT00513656
- Testing
- Oxycodone, Oxycodone/Naloxone
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Moderate to Severe Idiopathic RLS With Daytime Symptoms
Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms
The primary objective for the 12-week Titration-/Maintenance Period is: To demonstrate superior efficacy of OXN PR compared to PLA in the improvement of symptom severity of RLS.
- Trial name
- NCT01112644
- Testing
- Oxycodone naloxone prolonged release tablets (OXN PR)
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 205 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain, Constipation
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
The primary research objective is to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR tablets alone with cancer…
- Trial name
- NCT01438567
- Testing
- oxycodone/naloxone prolonged release (OXN PR) tablets, oxycodone prolonged release (OxyPR) tablets
- Where
- United Kingdom
- Volunteers
- 270 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Subjects With Moderate to Severe, Chronic Nonmalignant Pain
A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain
The primary objective was to demonstrate the superiority of OXN over placebo over time from the initial dose of study medication to multiple pain events (inadequate analgesia) during the double blind phase.
- Trial name
- NCT01971632
- Testing
- Oxycodone & naloxone combination, prolonged release
- Volunteers
- 463 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Healthy
Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
The purpose of this study is to estimate the effects of food and of sprinkling ALO-02 pellets on applesauce on the bioavailability of oxycodone and naltrexone/6- beta-naltrexol from an extended release pellets-in-capsule…
- Trial name
- NCT01456507
- Testing
- ALO-02 (Oxycodone Naltrexone)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
- Trial name
- NCT01677065
- Testing
- Oxycodone controlled-release test formulation, Immediate-release reference drug
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Driving Behavior
Opiates and Benzodiazepines on Driving
The aim of this research is to assess drug effects (Xanax and Norco) on driving performance. Researchers will use the Alertness Memory Profiler (AMP) application to compare results to previous related studies.
- Trial name
- NCT03447353
- Testing
- Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Timothy L. Brown
Moderate-severe Pain
Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
- Trial name
- NCT02680847
- Testing
- ALO-02
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pfizer